GlassScriptPhysician profile
Cheryl G Thurman
NPI 1912008251
$8,631.62
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,238 · 2022: $2,897 · 2023: $3,233 · 2024: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,496.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,062.67 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,327.07 | 2021-2024 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,161.79 | 2021-2023 | Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $815.08 | 2021-2023 | Entyvio, Gattex |
| Ironwood Pharmaceuticals, INC | $383.89 | 2021-2023 | Linzess |
| Genzyme Corporation | $356.90 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $347.41 | 2021-2023 | Dificid, Zerbaxa, Recarbrio |
| Ferring Pharmaceuticals INC. | $276.23 | 2021-2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $259.25 | 2022-2023 | Dupixent |
| Redhill Biopharma INC. | $179.84 | 2021-2022 | |
| Ardelyx, INC. | $179.57 | 2023 | Ibsrela |
| Qol Medical, LLC | $168.57 | 2021-2024 | Sucraid, Sucraid |
| Intercept Pharmaceuticals, INC. | $155.83 | 2021-2023 | Ocaliva |
| Celgene Corporation | $149.69 | 2023-2024 | Zeposia |
| Gilead Sciences, INC. | $147.29 | 2021-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $123.76 | 2021-2023 | Amjevita, Avsola |
| Pfizer INC. | $113.03 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $104.37 | 2022 | |
| Daiichi Sankyo INC. | $74.91 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $66.79 | 2022-2023 | |
| Csl Behring | $54.83 | 2021-2022 | |
| Fresenius Kabi USA, LLC | $31.94 | 2023 | Idacio |
| Sandoz INC. | $22.12 | 2023 | Hyrimoz |
| Organon LLC | $21.57 | 2021-2023 | Renflexis |
| Braintree Laboratories, INC. | $19.73 | 2024 | Suflave |
| Pharmacosmos Therapeutics INC. | $14.69 | 2021 | |
| Alfasigma USA, INC. | $12.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Thurman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.